Very early researchNot Yet RecruitingNCT07458919What this trial is testingTherapy for Advanced NSCLC With EGFR 19delins MutationWho this might be right forLung Cancer Fuzhou General Hospital 94
Testing effectiveness (Phase 2)Study completedNCT01260181What this trial is testingErlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsWho this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Looking for participantsNCT07079475What this trial is testingStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)Who this might be right forNon-Small Cell Lung Cancer Dizal (Jiangsu) Pharmaceutical Co., Ltd. 200
Not applicableEnded earlyNCT02483416What this trial is testingEvaluation of the Impact of Nurse-led Telephone on Treatment ComplianceWho this might be right forCarcinoma, Non-Small-Cell Lung Boehringer Ingelheim 30
Early research (Phase 1)Study completedNCT02729298What this trial is testingFirst-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal Carcinoma+2 more Sumitomo Pharma America, Inc. 177
Large-scale testing (Phase 3)Looking for participantsNCT07183189What this trial is testingSHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCWho this might be right forNon-small Cell Lung Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. 576
Large-scale testing (Phase 3)Ended earlyNCT04816214What this trial is testingStudy Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyWho this might be right forCarcinoma, Non-Small-Cell Lung Novartis Pharmaceuticals 6
Early research (Phase 1)Study completedNCT04959981What this trial is testingAnti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCWho this might be right forAdvanced Non-squamous Non-small-cell Lung Cancer Erasca, Inc. 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06463171What this trial is testingPhase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerWho this might be right forLung Cancer Non-small Cell Stage IV Shanghai Pulmonary Hospital, Shanghai, China 60
Large-scale testing (Phase 3)Active Not RecruitingNCT05607550What this trial is testingStudy to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Who this might be right forMetastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations ArriVent BioPharma, Inc. 398
Not applicableStudy completedNCT02991274What this trial is testingARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central LaboratoryWho this might be right forLocally Advanced or Metastatic EGFR(+) NSCLC Patients AstraZeneca 897
Not applicableStudy completedNCT00997230What this trial is testingEpidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or mWho this might be right forNewly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer AstraZeneca 4,243
Testing effectiveness (Phase 2)UnknownNCT03062800What this trial is testingStudy of Thalidomide in Treatment of Advanced Nsclc (Dream-003)Who this might be right forAdvanced Nsclc Qilu Hospital of Shandong University 232
Testing effectiveness (Phase 2)UnknownNCT01391260What this trial is testingRadiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer ZhuGuangYing 30
Testing effectiveness (Phase 2)Study completedNCT00891579What this trial is testingStudy of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) MutationsWho this might be right forNon Small Cell Lung Cancer Chinese Society of Lung Cancer 161
Large-scale testing (Phase 3)UnknownNCT02824458What this trial is testingGefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR MutationsWho this might be right forEGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors Sun Yat-sen University 246
Testing effectiveness (Phase 2)Study completedNCT02414139What this trial is testingStudy of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)Who this might be right forCarcinoma, Non-Small-Cell Lung Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)UnknownNCT04895930What this trial is testingFurmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCWho this might be right forNon-Small-Cell Lung Cancer Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01250119What this trial is testingAssess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.Who this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 688
Not applicableUnknownNCT06095934What this trial is testingEfficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI TreatmentWho this might be right forNSCLCEGFR Gene Mutation The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 20